uMotif adds eClinical industry veteran Steve Rosenberg to board of Directors

London, UK, August 4, 2021 – uMotif, a leading eClinical platform provider powering patient-centric research, today announced that Steve Rosenberg has joined its Board of Directors. Rosenberg has more than 40 years of life sciences and healthcare industry experience, leading the development and deployment of cloud-based solutions that include an integrated approach to clinical trial management, new methodologies for patient-reported outcomes, and the introduction of advanced analytics for at-risk healthcare payers and providers.

“Steve’s wealth of highly-relevant expertise, developing and scaling technologies that improve clinical trials and patient care, increases the breadth of strategic leadership, industry experience and operational excellence within our Board,” said Bruce Hellman, uMotif’s CEO “We’re honored that he is bringing his deep domain expertise, technology vision and insight to uMotif, as we continue to advance our platform’s capabilities and prepare for the next stage of growth.”

Rosenberg added: “uMotif is pioneering significant advances in clinical trial technology. I’m excited to contribute to the innovative work they are doing to empower patients, reduce the burden of participating in research and create a better, more engaging trial experience for them.”

A member of the Clinical Data Interchange Standards Consortium (CDISC) Board of Directors, as well as the Digital Health Advisory Board of the Prix Galien, Rosenberg, was most recently senior vice president and general manager of Oracle Health Sciences, a position he held from 2014 until he retired in July 2020. Prior to that and most notably, Rosenberg was the visionary and lead evangelist for the integrated clinical technology suite introduced by Phase Forward (acquired by Oracle in 2010) and used by nine of the top-10 global biopharmaceutical companies. As senior vice president of Software and Services at Phase Forward, Rosenberg led all product development, global services, hosting, helpdesk, and information technology, as well as company acquisitions – from identification to integration.

In February 2021, Rosenberg co-founded The One By One Project to support those who are underserved and at-risk in the Greater-Boston area. He is also on the board of the Brandon School & Residential Treatment Center and St. Ann’s Home & School in Massachusetts.

About uMotif

uMotif’s mission is to put patients at the centre of clinical research. Designed with patients for patients, the uMotif patient-centric eClinical platform powers site-based to fully decentralized clinical, real-world, and post-marketing research. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotechs, CROs, and academic institutions to capture eConsent and large volumes of ePRO, symptom, and wearable device data.

PR Contacts